Format

Send to

Choose Destination
Best Pract Res Clin Haematol. 2013 Sep;26(3):275-8. doi: 10.1016/j.beha.2013.10.001. Epub 2013 Oct 15.

The euphoria of hypomethylating agents in MDS and AML: is it justified?

Author information

1
Leukemia Program, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Electronic address: sekerem@ccf.org.

Abstract

While it is logical to use hypomethylating agents to treat patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), trial results with azacitidine and decitabine have been inconsistent. Azacitidine confers a survival benefit in higher-risk MDS patients, while decitabine does not. Neither agent has demonstrated a survival advantage in older AML patients in prospective studies. Reasons for this are explored here along with a recommendation to reconsider clinical trial design endpoints.

KEYWORDS:

AML; MDS; acute myeloid leukemia; azacitidine; cytarabine; decitabine; hypomethylating agents; myelodysplastic syndromes

PMID:
24309530
DOI:
10.1016/j.beha.2013.10.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center